ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Polymyalgia Rheumatica (PMR)"

  • Abstract Number: 2404 • ACR Convergence 2023

    Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk

    Eugenio De Miguel1, Rositsa Karalilova2, PIERLUIGI MACCHIONI3, Cristina Ponte4, Edoardo Conticini5, Alessandro Tomelleri6, Sara Monti7, Irene Monjo1, Zguro Batalov2, Giulia Klinowski8, Paolo Falsetti9, David Kane10, Corrado Campochiaro11 and Alojzija Hocevar12, 1Hospital Universitario La Paz, Madrid, Spain, 2Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 3Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 5Tallaght University Hospital, Dublin, Ireland, 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 7Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 8IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 9San Raffaele Scientific Institute, Siena, Italy, 10Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 11IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 12Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
  • Abstract Number: 0747 • ACR Convergence 2023

    Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4 and David Kane5, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
  • Abstract Number: 2516 • ACR Convergence 2023

    The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica

    Katrina Nguyen1, Jennifer Du1, Jiaxiao shi2 and Antony Lin1, 1Kaiser SCAL, Fontana, CA, 2SCPMG, Pasadena, CA

    Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
  • Abstract Number: 1036 • ACR Convergence 2023

    The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study

    Alojzija Hocevar1, PIERLUIGI MACCHIONI2, Irene Monjo3, Rositsa Karalilova4, Edoardo Conticini5, Alessandro Tomelleri6, Cristina Ponte7, Sara Monti8, Giulia Klinowski9, Zguro Batalov4, Paolo Falsetti10, Corrado Campochiaro11 and Eugenio De Miguel3, 1Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Hospital Universitario La Paz, Madrid, Spain, 4Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 5Tallaght University Hospital, Dublin, Ireland, 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 7Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 8Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 9IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 10San Raffaele Scientific Institute, Siena, Italy, 11IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy

    Background/Purpose: Musculoskeletal ultrasound (US) is a validated method for the objective assessment of the pathological changes occurring in PMR. It assists the diagnosis of the…
  • Abstract Number: 1054 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

    David Liew1, Aurora Poon1, Christopher McMaster2, Russell Buchanan1, Victor Yang1, Andrew Scott1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Pascoe Vale South, Australia, 3Austin Health, Malvern East, Australia

    Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
  • Abstract Number: 1098 • ACR Convergence 2023

    Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

    Kelly Tran1, Ellen Ann Sockman1, Rachel Salyer1, Megan Young1, Aisha Abbasi1 and Devanshu Verma2, 1West Virginia University Hospital, Morgantown, WV, 2West Virginia University, Morgantown, WV

    Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
  • Abstract Number: 1133 • ACR Convergence 2023

    Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

    William Rigby1, Todd Mackenzie2, Emily Campbell1, Joshua Skydel3, Bryan Savage1, Monica Dimambro2 and Vivekanand Tiwari1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth College, Hanover, NH, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
  • Abstract Number: 1201 • ACR Convergence 2023

    Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, David Kane3 and Richard Conway4, 1St James's Hospital, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Ireland, 3Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
  • Abstract Number: 1565 • ACR Convergence 2023

    Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4 and David Kane5, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
  • Abstract Number: 1566 • ACR Convergence 2023

    Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

    Christine Xu1, Ying Liu1, Jennifer Sloane2, Remco Diab3, Hubert van Hoogstraten1, Hisham Abdallah4, Sreeraj Macha1 and Bhaskar Dasgupta5, 1Sanofi, Bridgewater, NJ, 2Sanofi, Cambridge, MA, 3Sanofi, Rotkreuz, Switzerland, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Anglia Ruskin University, East Anglia, United Kingdom

    Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
  • Abstract Number: 1649 • ACR Convergence 2023

    Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis

    Lara Clarissa Burg1, Christian Dejaco2, Pantelis Karakostas3, Charlotte Behning4, Peter Brossart1 and Valentin Sebastian Schäfer3, 1University Hospital of Bonn, Bonn, Germany, 2Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, 3Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, 4Institute of Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany

    Background/Purpose: In recent years, ultrasound has become a standard tool in the diagnosis of giant cell arteritis (GCA). Typical findings are increased intima media thickness…
  • Abstract Number: 0027 • ACR Convergence 2023

    Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen

    Mehmet Hocaoglu1, Jamal Mikdashi2, James Perry2 and Charles Hong2, 1University of Maryland School of Medicine, Pittsburgh, PA, 2University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: The existing literature on the genetics of polymyalgia rheumatica (PMR) is limited to candidate gene studies with small sample sizes. There is a need…
  • Abstract Number: 1869 • ACR Convergence 2023

    FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients

    Andreas Wiggers Nielsen1, Ib Tønder Hansen2, Berit Dalsgaard Nielsen3, Søren Geill Kjær4, Jesper Blegvad-Nissen4, Christian Møller Sørensen3, Ellen-Margrethe Hauge1, Lars Christian Gormsen2 and Kresten Krarup Keller1, 1Aarhus University Hospital, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus N, Denmark, 3Department of Internal Medicine, Horsens, Denmark, 4Diagnostic Centre, Silkeborg, Denmark

    Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
  • Abstract Number: 0698 • ACR Convergence 2022

    Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women

    Jae Hee Kang1, Susan Malspeis2, Nicole Yang2 and Karen Costenbader2, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease among older White women, but little is known of its etiology and there are…
  • Abstract Number: 0761 • ACR Convergence 2022

    Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group

    Nilasha Ghosh1, Nina Couette2, Wouter van Binsbergen3, Sophia Weinmann4, Bridget Jivanelli1, Beverley Shea5, Anne Bass6, Karolina Benesova7, Clifton O. Bingham III8, Cassandra Calabrese9, Laura C. Cappelli10, Karmela Kim Chan1, Ernest Choy11, Dimitrios Daoussis12, Susan Goodman1, Marie Hudson13, Shahin Jamal14, Jan Leipe15, Maria A. Lopez-Olivo16, Maria Suarez-Almazor17, Conny van der Laken18, Alexa Meara19, David Liew20 and Marie Kostine21, 1Hospital for Special Surgery, New York, NY, 2Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, 3Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL, Amsterdam, Netherlands, 4Department of Rheumatology & Immunology, Duke University, Durham, NC, 5School of Epidemiology and Public Health, University of Ottawa, Ottawa, 6Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 7University Hospital Heidelberg, Heidelberg, Germany, 8Johns Hopkins University, Baltimore, MD, 9Cleveland Clinic Foundation, Cleveland Heights, OH, 10Johns Hopkins School of Medicine, Baltimore, MD, 11Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 12Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece, 13McGill University, Montréal, QC, Canada, 14University of British Columbia, Vancouver, BC, Canada, 15Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, 16The University of Texas, MD Anderson Cancer Center, Houston, TX, 17MD Anderson Cancer Center, Houston, TX, 18Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, 19The Ohio State University Wexner Medical Center, Columbus, OH, 20Austin Health, Heidelberg, Australia, 21Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France

    Background/Purpose: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology